Therapeutic use of the phosphate binder lanthanum carbonate

Bibliography

• Cozzolino M, Brancaccio D. Lanthanum carbonate–new data on parathyroid hormone control without liver damage. Nephrol Dial Transplant 2007;22(2):316-8
   PubMedGoogle Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4):607-17
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-18
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201
   PubMedGoogle Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
   PubMed Web of Science ®Google Scholar
• Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179-87
   PubMed Web of Science ®Google Scholar
• London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15(7):1943-51
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72(9):1130-7
   PubMed Web of Science ®Google Scholar
• Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3(1):61-8
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005;100(1):c8-19
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102(2):c61-71
   PubMed Web of Science ®Google Scholar
• Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65(3):191-202
   PubMed Web of Science ®Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96(10):2818-27
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004;19(7):1902-6
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005;21(5):657-64
   PubMed Web of Science ®Google Scholar
• Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63(6):461-70
   PubMed Web of Science ®Google Scholar
• Altmann P, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007;71(3):252-9
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-8
   PubMedGoogle Scholar
• Bervoets AR, Oste L, Behets GJ, et al. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone 2006;38(6):803-10
   PubMed Web of Science ®Google Scholar
• Fiddler G. Low systemic absorption of lanthanum and excellent tolerability during administration of 3 g lanthanum as Fosrenol for 5 days. J Am Soc Nephrol 2002;13:751A
   Google Scholar
• Pennick M, Dennis K, Damment SJ. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006;46(7):738-46
   PubMed Web of Science ®Google Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42(1):96-107
   PubMed Web of Science ®Google Scholar
• Damment SJ, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett 2007;171(1-2):69-77
   PubMed Web of Science ®Google Scholar
• Fiddler G. Fosrenol (lanthanum carbonate) does not affect the pharmacokinetics of concomitant treatment with warfarin. J Am Soc Nephrol 2002;13:749
   Google Scholar
• Fiddler G. Fosrenol (lanthanum carbonate) does not affect the pharmacokinetics of concomitant treatment with digoxin. J Am Soc Nephrol 2002;13:749
   Google Scholar
• Fiddler G, Taubel J. No pharmacokinetic interaction between lanthanum carbonate and metoprolol. Am J Kidney Dis 2003;41:18
   PubMedGoogle Scholar
• How PP, Fischer JH, Arruda JA, et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2007;2(6):1235-40
   PubMed Web of Science ®Google Scholar
• Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005;20(4):775-82
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62(3):193-201
   PubMed Web of Science ®Google Scholar
• Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008;12(1):55-61
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110(1):c15-23
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: A Multicenter Study. Clin J Am Soc Nephrol 2008
   Google Scholar
• Behets GJ, Verberckmoes SC, Oste L, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005;67(5):1830-6
   PubMed Web of Science ®Google Scholar
• Damment SJ, Shen V. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 2005;63(2):127-37
   PubMed Web of Science ®Google Scholar
• Damment SJ, Gill M, Confer S, et al. The bone kinetics of lanthanum in dialysis patients treated with lanthanum carbonate for up to 4.5 years. J Am Soc Nephrol 2004;15:271
   Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21(8):2217-24
   PubMed Web of Science ®Google Scholar
• Bronner F, Slepchenko BM, Pennick M, et al. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47(8):543-52
   PubMed Web of Science ®Google Scholar
• Behets GJ, Dams G, Vercauteren SR, et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004;15(8):2219-28
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68(6):2809-13
   PubMed Web of Science ®Google Scholar
• Lacour B, Lucas A, Auchere D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005;67(3):1062-9
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, D'Haese P, De Broe M. Lanthanum data in perspective. Kidney Int 2006;70(7):1382; author reply 1383
   PubMed Web of Science ®Google Scholar
• Mc Leod C, Cox A, Bramall N. The need for contamination control in studies on lanthanum biodisposition. Kidney Int 2005;68(6):2906; author reply 2906-7
   PubMedGoogle Scholar
• Yang Z, Schryvers D, Roels F, et al. Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 2006;223(Pt 2):133-9
   PubMed Web of Science ®Google Scholar
• Pereira AA, Weiner DE, Scott T, et al. Cognitive function in dialysis patients. Am J Kidney Dis 2005;45(3):448-62
   PubMed Web of Science ®Google Scholar
• Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46(5):925-32
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16(6):1788-93
   PubMed Web of Science ®Google Scholar
• Guerin AP, Pannier B, Marchais SJ, et al. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens 2006;15(2):105-10
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
   PubMed Web of Science ®Google Scholar
• St Peter WL, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51(3):445-54
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008
   Google Scholar
• Neven E, De Clerck PA, et al. Lanthanum (La) carbonate treatment prevents the development of vascular calcification (VC) in rats with adenine-induced chronic renal failure. J Am Soc Nephrol 2007;18:SU-P0721
   Google Scholar
• Joy MS, Finn WF. Fosrenol, a Novel Non-Calcium, Non-Aluminum Phosphate Binder, Has a Good Safety and Efficacy Profile in the Long-Term Treatment of Hyperphosphatemia in Hemodialysis Patients. J Am Soc Nephrol 2002;13:386A
   Google Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65(5):1914-26
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51(6):952-65
   PubMed Web of Science ®Google Scholar